Search company, investor...

Advanced BioSensors


Incubator/Accelerator | Alive

About Advanced BioSensors

Advanced BioSensors is developing a miniaturized blood glucose sensor for use in the treatment of diabetes.

Headquarters Location

6849 Bellflower Court

Mentor, Ohio, 44060,

United States


Missing: Advanced BioSensors's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Advanced BioSensors's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Advanced BioSensors

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Advanced BioSensors is included in 1 Expert Collection, including Diabetes.



1,904 items

Advanced BioSensors Patents

Advanced BioSensors has filed 9 patents.

patents chart

Application Date

Grant Date


Related Topics




Fiber optics, Spectroscopy, Molecular biology, Gas discharge lamps, Radio electronics


Application Date


Grant Date



Related Topics

Fiber optics, Spectroscopy, Molecular biology, Gas discharge lamps, Radio electronics



Advanced BioSensors Frequently Asked Questions (FAQ)

  • Where is Advanced BioSensors's headquarters?

    Advanced BioSensors's headquarters is located at 6849 Bellflower Court, Mentor.

  • What is Advanced BioSensors's latest funding round?

    Advanced BioSensors's latest funding round is Incubator/Accelerator.

  • Who are the investors of Advanced BioSensors?

    Investors of Advanced BioSensors include MAGNET Innovation Center.

  • Who are Advanced BioSensors's competitors?

    Competitors of Advanced BioSensors include Sotera Wireless, OptiScan Biomedical, Vytrace, Novoculi, ArKal Medical and 9 more.

Compare Advanced BioSensors to Competitors

ArKal Medical

Arkal Medical is developing a continuous blood glucose sensor for diabetes.

Luminous Medical

Luminous Medical is developing a new device to allow the near continuous measurement of blood glucose and other analytes in the hospital environment.


Speckodyne Corp aims to be a provider of continuous real-time blood coagulability monitoring technology in Operation Room, Catheterization Lab or Intensive Care Unit settings. Based on a approach developed at UCF's College of Optics & Photonics, Speckodyne's blood coagulability monitor uses optical fiber and solid-state optics technology, leading to a robust, relatively inexpensive design that can be easily integrated with existing interventional devices such as catheters and guidewires, as well as bed-side or laboratory equipment.

Glucose Sensing Technologies

Vytrace Corporation (fka Glucose Sensing Technologies) is developing a new critical care monitor to monitor glucose at the bedside of critically ill patients in the Intensive Care Unit. The product is designed specifically for patients in the ICU. This is not a consumer product for diabetic glucose monitoring. They also are exploring other analytes that may be monitored with their sensor technology. Vytrace Corporation has a highly accurate bedside monitor that automatically and continuously monitors blood glucose via a fiberoptic catheter with a photonic crystal sensor on the tip.

Sotera Wireless

Sotera Wireless is committed to the development, marketing and sale of a new generation early detection surveillance monitoring system. Its flagship product, the ViSi Mobile, is designed to improve patient safety by detecting early signs of deterioration in virtually any care setting, enabling early intervention and rapid response without limiting the patient's freedom of movement

Bay Area Digital Logo
Bay Area Digital

Bay Area Digital is a company that received a SBIR Phase I grant for a project entitled: Talking Blood Glucose Meter with full Accessibility for Blind, Visually and Cognitively Impaired. Their Project addresses a crisis in the lack of effective glucose monitoring equipment for visually and cognitively impaired diabetics. The proposal thoroughly examines the technical and commercial feasibility of developing innovative technology that enables such patients to reliably use information provided by a state-of-the-art blood glucose meter, using speech output that is coupled with a commercially developed meter. There are currently no state-of-the-art or best-of-breed blood glucose meter systems available in the U.S. market with speech capabilities for use by the cognitively, visually impaired or blind community. The development of such a meter will positively impact the self-management of diabetes mellitus, improving quality of life and clinical outcomes for patients and preventing the development of secondary complications and provide an opportunity to impact a major health problem affecting millions of U.S. citizens.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.